ATE179614T1 - Herpes simplex virus vp16 impfstoffe - Google Patents

Herpes simplex virus vp16 impfstoffe

Info

Publication number
ATE179614T1
ATE179614T1 AT91914945T AT91914945T ATE179614T1 AT E179614 T1 ATE179614 T1 AT E179614T1 AT 91914945 T AT91914945 T AT 91914945T AT 91914945 T AT91914945 T AT 91914945T AT E179614 T1 ATE179614 T1 AT E179614T1
Authority
AT
Austria
Prior art keywords
herpes simplex
simplex virus
vaccines
compositions
hsv
Prior art date
Application number
AT91914945T
Other languages
English (en)
Inventor
Rae Lynn Burke
Rose E Sekulovich
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Application granted granted Critical
Publication of ATE179614T1 publication Critical patent/ATE179614T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT91914945T 1990-08-02 1991-07-30 Herpes simplex virus vp16 impfstoffe ATE179614T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56152890A 1990-08-02 1990-08-02

Publications (1)

Publication Number Publication Date
ATE179614T1 true ATE179614T1 (de) 1999-05-15

Family

ID=24242345

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91914945T ATE179614T1 (de) 1990-08-02 1991-07-30 Herpes simplex virus vp16 impfstoffe

Country Status (12)

Country Link
US (2) US5714152A (de)
EP (1) EP0541692B1 (de)
JP (3) JP3005292B2 (de)
AT (1) ATE179614T1 (de)
CA (1) CA2088600C (de)
DE (1) DE69131200T2 (de)
DK (1) DK0541692T3 (de)
ES (1) ES2134197T3 (de)
GR (1) GR3030834T3 (de)
IE (1) IE912744A1 (de)
PT (1) PT98565B (de)
WO (1) WO1992002251A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
GB9119940D0 (en) * 1991-09-18 1991-10-30 Hare Peter F J O Polypeptide inhibitor of viral replication
US5965354A (en) * 1995-07-28 1999-10-12 Chiron Corporation Herpes simplex virus diagnostics
US5980912A (en) * 1997-03-25 1999-11-09 Zonagen, Inc. Chitosan induced immunopotentiation
EP0984790A1 (de) 1997-06-02 2000-03-15 Chiron Corporation Impfstoff gegen herpes simplex viren enthaltend vp22 und dessen verwendungen
US6087166A (en) * 1997-07-03 2000-07-11 Basf Aktiengesellschaft Transcriptional activators with graded transactivation potential
DE69933200T2 (de) * 1998-03-09 2007-02-22 Glaxosmithkline Biologicals S.A. Kombinierte impfstoffzusammensetzungen
KR20010085348A (ko) 1998-08-07 2001-09-07 추후보정 면역능을 갖는 헤르페스 심플렉스 바이러스 항원 및 이를이용하는 방법
US6860615B2 (en) * 1999-01-06 2005-03-01 Armament Systems And Procedures, Inc. LED flashlight with integral keyring clip
US6569616B1 (en) * 1999-07-29 2003-05-27 Wisconsin Alumni Research Foundation Human cytomegalovirus glycoprotein O as a new drug target and subunit vaccine candidate
JP2003512305A (ja) 1999-09-30 2003-04-02 ユニバーシティ オブ ワシントン 免疫学的に重要な単純疱疹ウイルス抗原
ATE488249T1 (de) 2001-07-31 2010-12-15 Univ Washington Immunologisch bedeutende herpes-simplex-virus- antigene und verfahren für ihre verwendung
KR100420501B1 (ko) * 2001-09-26 2004-03-02 한국지질자원연구원 벤토나이트로부터 몬모릴로나이트 광물의 분리·회수 방법
CA2486553C (en) * 2002-06-17 2012-01-10 Taro Pharmaceuticals U.S.A., Inc. Ibuprofen suspension
AU2004274430A1 (en) 2003-09-12 2005-03-31 Antigenics, Inc. Vaccine for treatment and prevention of herpes simplex virus infection
US8460674B2 (en) 2009-02-07 2013-06-11 University Of Washington HSV-1 epitopes and methods for using same
US9044447B2 (en) 2009-04-03 2015-06-02 University Of Washington Antigenic peptide of HSV-2 and methods for using same
MY159500A (en) * 2009-05-22 2017-01-13 Genocea Biosciences Inc Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
WO2012074881A2 (en) 2010-11-24 2012-06-07 Genocea Biosciences, Inc. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
WO2013078299A1 (en) 2011-11-23 2013-05-30 Genocea Biosciences, Inc. Nucleic acid vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
JP2019537555A (ja) 2016-09-28 2019-12-26 ジェノセア バイオサイエンシーズ， インコーポレイテッド ヘルペスを処置するための方法および組成物
US10745931B1 (en) 2019-08-14 2020-08-18 Premises Innovations Llc Self-rightening post system

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4818694A (en) * 1982-07-20 1989-04-04 American Cyanamid Company Production of herpes simplex viral protein
US4891315A (en) * 1982-10-25 1990-01-02 American Cyanamid Company Production of herpes simplex viral porteins
AU1678783A (en) * 1982-07-20 1984-01-26 Molecular Genetics, Inc. Production of herpes simplex viral proteins
DE3461928D1 (en) * 1983-06-23 1987-02-12 Person Stanley Immunologically reactive non-glycosylated amino acid chains of glycoprotein b of herpes virus types 1 and 2
NZ209308A (en) * 1983-08-30 1991-08-27 Genentech Inc Vaccine against hsv involving a truncated membrane-free derivative of a membrane-bound protein
JPS6051120A (ja) * 1983-08-31 1985-03-22 Chemo Sero Therapeut Res Inst 単純ヘルペスサブユニットワクチン
US4642333A (en) * 1983-09-16 1987-02-10 Stanley Person Immunologically reactive non-glycosylated amino acid chains of glycoprotein B of herpes virus types 1 and 2
US4855224A (en) * 1984-03-09 1989-08-08 Genentech, Inc. Molecularly cloned diagnostic product and method of use
US4618578A (en) * 1984-07-17 1986-10-21 Chiron Corporation Expression of glycoprotein D of herpes simplex virus
US5171568A (en) * 1984-04-06 1992-12-15 Chiron Corporation Recombinant herpes simplex gb-gd vaccine
ATE230798T1 (de) * 1984-04-06 2003-01-15 Chiron Corp Rekombinanter herpes simplex gb-gd-impfstoff
FR2563434B1 (fr) * 1984-04-25 1986-07-25 Transgene Sa Vaccin contre la rage et procede pour sa preparation
US4859587A (en) * 1984-06-04 1989-08-22 Institut Merieux Recombinant herpes simplex viruses, vaccines and methods
JPH0668B2 (ja) * 1985-08-30 1994-01-05 財団法人化学及血清療法研究所 単純ヘルペスウイルス遺伝子が組込まれた組換えプラスミド
ATE136468T1 (de) * 1986-10-20 1996-04-15 Chiron Corp Impfstoff zur behandlung von hsv
GB8917029D0 (en) * 1989-07-25 1989-09-13 Marie Curie Memorial Foundatio Polypeptide inhibitor of viral replication

Also Published As

Publication number Publication date
GR3030834T3 (en) 1999-11-30
WO1992002251A1 (en) 1992-02-20
JP2002136297A (ja) 2002-05-14
EP0541692B1 (de) 1999-05-06
DE69131200D1 (en) 1999-06-10
EP0541692A4 (en) 1993-12-08
PT98565A (pt) 1992-06-30
CA2088600C (en) 1999-11-16
EP0541692A1 (de) 1993-05-19
DE69131200T2 (de) 1999-12-09
JPH06502989A (ja) 1994-04-07
IE912744A1 (en) 1992-02-12
ES2134197T3 (es) 1999-10-01
US5795579A (en) 1998-08-18
DK0541692T3 (da) 1999-11-01
US5714152A (en) 1998-02-03
JP3005292B2 (ja) 2000-01-31
CA2088600A1 (en) 1992-02-03
JPH11308998A (ja) 1999-11-09
PT98565B (pt) 1999-01-29

Similar Documents

Publication Publication Date Title
ATE179614T1 (de) Herpes simplex virus vp16 impfstoffe
ES2176232T3 (es) Vacuna adecuada para ser utilizada en la prevencion y tratamiento de la infeccion por helicobacter.
UA66744C2 (en) 5,6-dichlorobenzimidazole derivatives, methods for the preparation thereof, pharmaceutical composition and method for treatment of viral infections
NL300185I1 (nl) Acellulair vaccin.
NO912825D0 (no) Fremgangsmaate for fremstilling av cokonjugate vaksiner omfattende immunogenisk protein, hiv-beslektede peptider og anioniske grupper.
DK0610286T3 (da) Rekombinante immunotoxiner
AR005750A1 (es) Composicion farmaceutica para tratar o prevenir infecciones con zoster en personas infectadas con el virus de varicela zoster y procedimiento para preparar dicha composicion
DE69332111D1 (de) Darmprotozoen-Impfstoffe
DK0385909T3 (da) Kit eller middel til forebyggelse eller behandling af HIV-1-infektioner
NO930401L (no) Peptider som blokkerer hiv-infeksjoner og metoder for bruk derav
DK0459176T3 (da) Oligophosphater med antiviral virkning

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee